MarketCap
Facebook
X
TelegramAnnual report 2022
added 02-27-2023
Country |
 USA |
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
90.3 M |
Market Cap[1] |
$ 7.81 M |
EBITDA (LTM) |
$ -191 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
-2.32 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Burford Capital Limited
BUR
|
$ 4.73 | 0.42 % | $ 761 M | NYSE |  Britain |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 333.39 | -1.77 % | $ 43.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.17 | 3.93 % | $ 5.22 M | NYSE American |  Israel |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.73 | 3.04 % | $ 8.97 B | Nasdaq Capital Market |  Australia |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Aligos Therapeutics
ALGS
|
$ 7.42 | -15.1 % | $ 73.3 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 21.68 | 1.4 % | $ 1.01 B | Nasdaq Global Select Market | USA |
 |
Cabaletta Bio
CABA
|
$ 3.4 | 4.29 % | $ 342 M | Nasdaq Global Select Market | USA |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
 |
BioNTech SE
BNTX
|
$ 99.47 | 1.08 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
ContraFect Corporation
CFRX
|
- | -5.16 % | $ 5.39 M | Nasdaq Capital Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Akebia Therapeutics
AKBA
|
- | - | $ 399 M | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.24 | 2.17 % | $ 453 M | Nasdaq Global Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.58 | -2.03 % | $ 3.13 B | Nasdaq Global Select Market,SPB | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.49 | 0.68 % | $ 397 M | Nasdaq Global Select Market | Britain |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | USA |
 |
Celldex Therapeutics
CLDX
|
$ 33.87 | 1.62 % | $ 2.25 B | Nasdaq Global Select Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | USA |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.